• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

青年期霍奇金淋巴瘤患者存在复发风险:霍奇金淋巴瘤迟发复发的综合分析。

Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma.

机构信息

Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

出版信息

J Cancer Res Clin Oncol. 2018 May;144(5):935-943. doi: 10.1007/s00432-018-2613-9. Epub 2018 Feb 21.

DOI:10.1007/s00432-018-2613-9
PMID:29468437
Abstract

PURPOSE

Majority of relapses in Hodgkin lymphoma (HL) occur within 3 years after initial treatment, late relapses (LR), happening 5 or more years after first diagnosis is rare events. Neither clinical characteristics, risk factors, nor optimal treatment is well described for LR patients. Our aim was to provide a comprehensive analysis on the LR of HL to outline a patient population at risk of relapsing late.

PATIENTS AND METHODS

637 HL patients were treated at the University of Debrecen between 1981 and 2010. Patient data was evaluated retrospectively. Survival analysis was performed using the Kaplan-Meier method and odds ratios (OR) were identified by binary logistic regression models.

RESULTS

With a median observational time of 9.08 years 584 (91%) HL patients achieved complete remission (CR) after first line treatment. Relapse occurred in 176 (28%) patients, 26 (4%) of them 5 or more years after first diagnosis. With multivariable analysis, initial diagnosis before the age of 24 (p < 0.001), initial presentation between 1981 and 1990 or 1991-2000 (p = 0.025 and p = 0.023, respectively) and first line treatment with radiotherapy only (p = 0.034) were identified as independent risk factors for LR. We observed a significantly impaired OS for patients with early relapse HL compared to those in long-term remission or experiencing LR (p < 0.001).

CONCLUSION

Late relapse of HL presents with clinical characteristics very similar to primary disease and appears to have a good prognosis. First diagnosis in childhood or young adulthood and first line treatment before the ABVD era increases the risk of relapsing late.

摘要

目的

霍奇金淋巴瘤(HL)的大多数复发发生在初始治疗后 3 年内,而首次诊断后 5 年或更长时间发生的晚期复发(LR)则较为罕见。对于 LR 患者,其临床特征、危险因素和最佳治疗方法均未得到很好的描述。我们的目的是对 HL 的 LR 进行全面分析,以确定有复发风险的患者群体。

患者和方法

1981 年至 2010 年,在德布勒森大学治疗了 637 例 HL 患者。回顾性评估患者数据。采用 Kaplan-Meier 方法进行生存分析,采用二项逻辑回归模型确定优势比(OR)。

结果

中位观察时间为 9.08 年,584 例(91%)HL 患者在一线治疗后达到完全缓解(CR)。176 例(28%)患者发生复发,其中 26 例(4%)在首次诊断后 5 年或更长时间发生复发。多变量分析显示,24 岁以下的初始诊断(p<0.001)、1981 年至 1990 年或 1991 年至 2000 年首次发病(p=0.025 和 p=0.023)以及仅接受放疗的一线治疗(p=0.034)是 LR 的独立危险因素。我们观察到早期复发 HL 患者的 OS 明显低于长期缓解或发生 LR 的患者(p<0.001)。

结论

HL 的晚期复发具有与原发性疾病非常相似的临床特征,且预后良好。儿童或青年期的首次诊断和 ABVD 时代之前的一线治疗增加了晚期复发的风险。

相似文献

1
Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma.青年期霍奇金淋巴瘤患者存在复发风险:霍奇金淋巴瘤迟发复发的综合分析。
J Cancer Res Clin Oncol. 2018 May;144(5):935-943. doi: 10.1007/s00432-018-2613-9. Epub 2018 Feb 21.
2
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.未治疗的霍奇金淋巴瘤患者化疗和放疗在第二原发性恶性肿瘤、总生存期和无进展生存期方面的优化:个体参与者数据分析
Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD008814. doi: 10.1002/14651858.CD008814.pub2.
3
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.对早期预后不良或晚期霍奇金淋巴瘤患者,比较包括强化BEACOPP方案的一线化疗与包括ABVD方案的化疗。
Cochrane Database Syst Rev. 2017 May 25;5(5):CD007941. doi: 10.1002/14651858.CD007941.pub3.
4
High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.复发/难治性霍奇金淋巴瘤患者接受大剂量化疗后进行自体干细胞移植。
Cochrane Database Syst Rev. 2013 Jun 20;2013(6):CD009411. doi: 10.1002/14651858.CD009411.pub2.
5
Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.正电子发射断层扫描适配疗法用于霍奇金淋巴瘤患者的一线治疗
Cochrane Database Syst Rev. 2015 Jan 9;1(1):CD010533. doi: 10.1002/14651858.CD010533.pub2.
6
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).纳武单抗用于成人霍奇金淋巴瘤(使用RobotReviewer软件进行的快速综述)
Cochrane Database Syst Rev. 2018 Jul 12;7(7):CD012556. doi: 10.1002/14651858.CD012556.pub2.
7
Clinical features and outcomes of newly diagnosed classical Hodgkin lymphoma patients in Saudi Arabia: a multicenter cohort study.沙特阿拉伯新诊断的经典型霍奇金淋巴瘤患者的临床特征与结局:一项多中心队列研究
Sci Rep. 2025 May 26;15(1):18308. doi: 10.1038/s41598-025-02577-9.
8
Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma.正电子发射断层扫描适配疗法用于成人霍奇金淋巴瘤的一线治疗
Cochrane Database Syst Rev. 2025 Mar 26;3(3):CD010533. doi: 10.1002/14651858.CD010533.pub3.
9
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
10
Autologous hematopoietic stem cell transplantation following high dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas.非横纹肌肉瘤软组织肉瘤大剂量化疗后的自体造血干细胞移植。
Cochrane Database Syst Rev. 2013 Aug 7;2013(8):CD008216. doi: 10.1002/14651858.CD008216.pub4.

引用本文的文献

1
Stage-adapted treatment of HIV-associated Hodgkin lymphoma: Long-term results of a prospective, multicenter study.HIV相关霍奇金淋巴瘤的分期适应性治疗:一项前瞻性多中心研究的长期结果
Hemasphere. 2024 Jul 3;8(7):e68. doi: 10.1002/hem3.68. eCollection 2024 Jul.
2
Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors.接受化疗联合或不联合放疗治疗的霍奇金淋巴瘤的极晚期复发:线性模式及独特的预后因素
Blood Cancer J. 2022 Jul 5;12(7):102. doi: 10.1038/s41408-022-00674-w.
3
Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry.

本文引用的文献

1
Employment status and health related quality of life among Hodgkin-lymphoma survivors'- results based on data from a major treatment center in Hungary.霍奇金淋巴瘤幸存者的就业状况与健康相关生活质量——基于匈牙利一家主要治疗中心数据的结果
Health Qual Life Outcomes. 2017 Sep 19;15(1):180. doi: 10.1186/s12955-017-0758-x.
2
Late relapse of Hodgkin's lymphoma - is it different in clinical characteristics and outcome?霍奇金淋巴瘤的晚期复发——其临床特征和预后是否有所不同?
J BUON. 2017 Mar-Apr;22(2):481-486.
3
Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials.
霍奇金淋巴瘤初始治疗后发生的淋巴恶性肿瘤晚期复发 - 丹麦淋巴瘤登记处的一项研究。
Br J Haematol. 2022 Jul;198(1):50-61. doi: 10.1111/bjh.18180. Epub 2022 Apr 8.
4
Successful treatment with brentuximab vedotine for a patient with very late relapse of limited stage classic Hodgkin lymphoma.用维布妥昔单抗成功治疗一名晚期复发的局限期经典型霍奇金淋巴瘤患者。
Int Cancer Conf J. 2021 Sep 15;11(1):27-30. doi: 10.1007/s13691-021-00510-1. eCollection 2022 Jan.
经典型霍奇金淋巴瘤的晚期复发:德国霍奇金研究组 HD7 至 HD12 试验分析。
J Clin Oncol. 2017 May 1;35(13):1444-1450. doi: 10.1200/JCO.2016.71.3289. Epub 2017 Feb 27.
4
No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.对于首次缓解的霍奇金淋巴瘤患者,常规监测成像无生存获益:一项基于丹麦-瑞典人群的观察性研究。
Br J Haematol. 2016 Apr;173(2):236-44. doi: 10.1111/bjh.13943. Epub 2016 Feb 5.
5
Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia.细胞骨架紊乱导致不同形式的Glanzmann血小板无力症出现血小板功能障碍和血小板减少。
Haematologica. 2016 Jan;101(1):46-56. doi: 10.3324/haematol.2015.130849. Epub 2015 Oct 9.
6
Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.结节性淋巴细胞为主型霍奇金淋巴瘤:一项淋巴瘤研究协会的回顾性研究。
Haematologica. 2015 Dec;100(12):1579-86. doi: 10.3324/haematol.2015.133025. Epub 2015 Oct 1.
7
Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass.处于首次缓解期的霍奇金淋巴瘤患者:对于无残留肿块的患者,常规正电子发射断层扫描/计算机断层扫描成像并不优于临床随访。
Br J Haematol. 2014 Mar;164(5):694-700. doi: 10.1111/bjh.12687. Epub 2013 Dec 7.
8
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment.蒽环类药物心脏毒性:患病率、发病机制与治疗
Curr Cardiol Rev. 2011 Nov;7(4):214-20. doi: 10.2174/157340311799960645.
9
Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs.在处于首次缓解期的霍奇金淋巴瘤患者中进行正电子发射断层扫描/计算机断层扫描监测,其阳性预测值较低,成本较高。
Haematologica. 2012 Jun;97(6):931-6. doi: 10.3324/haematol.2011.056010. Epub 2011 Dec 29.
10
Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era.在 ABVD 治疗时代,霍奇金淋巴瘤(HL)患者接受大剂量自体干细胞移植(HD-ASCT)后晚期复发。
Biol Blood Marrow Transplant. 2012 Apr;18(4):640-7. doi: 10.1016/j.bbmt.2011.08.012. Epub 2011 Aug 24.